Key Highlights

  • Loss per share was USD 0.24 against an estimate of a USD 0.38 loss.
  • Revenue was USD 138 thousand against an estimate of USD 500 thousand.
  • Net loss was USD 10.74 million, compared with USD 19.42 million.
  • Research and development expenses were USD 6.55 million, against USD 15.92 million.

Vistagen Therapeutics (NASDAQ:VTGN) reported a loss per share of USD 0.24 for its fiscal second quarter of 2027, which ended September 30, 2026, against an estimate of a USD 0.38 loss. Revenue was USD 138 thousand, against an estimate of USD 500 thousand and USD 258 thousand in the prior-year quarter.

The net loss was USD 10.74 million, compared with USD 19.42 million, and the loss from operations was USD 10.94 million, compared with USD 20.05 million.

Operating Expenses

Research and development expenses were USD 6.55 million, compared with USD 15.92 million, and general and administrative expenses were USD 4.52 million, compared with USD 4.40 million. Total operating expenses were USD 11.08 million, compared with USD 20.31 million.

Interest income, net, was USD 198 thousand, compared with USD 630 thousand. The comprehensive loss was USD 10.74 million, compared with USD 19.40 million.

Six-Month Results

For the six months ended September 30, 2026, revenue was USD 1.61 million, compared with USD 502 thousand. Research and Development expenses were USD 17.46 million, compared with USD 27.69 million, and general and administrative expenses were USD 8.44 million, compared with USD 8.67 million.

Total operating expenses for the six months were USD 25.90 million, compared with USD 36.36 million, and the loss from operations was USD 24.28 million, compared with USD 35.86 million. The net loss was USD 23.77 million, compared with USD 34.51 million. Net cash used in Operating Activities was USD 26.87 million, compared with USD 32.61 million.

Balance Sheet

Cash and cash equivalents were USD 10.89 million, compared with USD 30.79 million at March 31, 2026, and marketable securities were USD 9.14 million, compared with USD 14.61 million. Total current Assets were USD 22.29 million, compared with USD 46.94 million, and total assets were USD 23.42 million, compared with USD 48.56 million.

Accounts payable were USD 1.08 million, compared with USD 1.54 million, and accrued expenses were USD 6.64 million, compared with USD 8.76 million. Total liabilities were USD 8.43 million, compared with USD 13.04 million, and total stockholders' Equity was USD 14.99 million, compared with USD 35.52 million.

The filing describes warrants issued with the October 2023 public offering, including warrants to purchase up to 9,294,022 shares of common stock at an exercise price of USD 5.38 per share and warrants to purchase 11,265,086 shares at USD 8.877 per share, and states that net proceeds from that offering were approximately USD 93.5 million after deducting related expenses. It states that the warrants were immediately exercisable upon issuance and that holders of the remaining warrants may elect to exercise them for pre-funded warrants.

Vistagen Therapeutics Fiscal Q2 2027 Earnings: Key Takeaways

Vistagen Therapeutics reported a fiscal second quarter 2027 loss per share of USD 0.24 and a net loss of USD 10.74 million. Cash and cash equivalents were USD 10.89 million, and marketable securities were USD 9.14 million.